Quratis Inc. Logo

Quratis Inc.

Develops infectious disease vaccines and offers biologics CDMO services for global health.

348080 | KO

Overview

Corporate Details

ISIN(s):
KR7348080003
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 의료단지길 143 -, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quratis Inc. is a biopharmaceutical company specializing in the development of innovative vaccines for infectious diseases and providing advanced biologics manufacturing services. The company's R&D pipeline focuses on next-generation vaccines for global health threats, including tuberculosis (TB), COVID-19, and other neglected tropical diseases. In addition to its proprietary development, Quratis operates as a Contract Development and Manufacturing Organization (CDMO), leveraging its state-of-the-art GMP-certified facilities. It offers comprehensive bench-to-field support, from research and process optimization to commercial-scale production, with expertise in platforms such as mRNA-LNP drug delivery. Through strategic global partnerships, Quratis aims to deliver high-quality, accessible, life-saving solutions worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-06-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 179.5 KB
2025-06-19 00:00
Regulatory News Service
신규시설투자등
Korean 7.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.0 MB
2025-05-09 00:00
Regulatory News Service
조회공시요구(현저한시황변동)에대한답변(중요정보없음)
Korean 4.7 KB
2025-05-08 00:00
Regulatory News Service
조회공시요구(현저한시황변동)
Korean 3.5 KB
2025-05-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 183.5 KB
2025-04-17 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.6 MB
2025-04-08 00:00
Annual Report
[기재정정]사업보고서 (2023.12)
Korean 1.5 MB
2025-04-07 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 492.3 KB
2025-04-07 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB
2025-04-07 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 31.5 KB
2025-04-07 00:00
Audit Report / Information
[기재정정]감사보고서제출
Korean 36.6 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.7 KB

Automate Your Workflow. Get a real-time feed of all Quratis Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quratis Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quratis Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia
SKF

Talk to a Data Expert

Have a question? We'll get back to you promptly.